Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Current Rheumatology Reports
Erschienen in: Current Rheumatology Reports 7/2021

01.07.2021 | Inflammatory Muscle Disease (L Diederichsen and H Chinoy, Section Editor)

Updates on the Immunopathology in Idiopathic Inflammatory Myopathies

verfasst von: Akinori Uruha, Hans-Hilmar Goebel, Werner Stenzel

Erschienen in: Current Rheumatology Reports | Ausgabe 7/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

To review recent advances in immunopathology for idiopathic inflammatory myopathies, focusing on widely available immunohistochemical analyses.

Recent Findings

Sarcoplasmic expression of myxovirus resistance protein A (MxA) is specifically observed in all types of dermatomyositis and informs that type I interferons are crucially involved in its pathogenesis. It is a more sensitive diagnostic marker than perifascicular atrophy. Diffuse tiny dots in the sarcoplasm highlighted by p62 immunostaining are characteristically seen in immune-mediated necrotizing myopathy. This feature is linked to a chaperone-assisted selective autophagy pathway. Myofiber invasion by highly differentiated T cells, a marker of which is KLRG1, is specific to inclusion body myositis and has a crucial role in its pathogenesis.

Summary

The recent advances in immunopathology contribute to increased diagnostic accuracy and a better understanding of the underlying pathophysiology in different types of idiopathic inflammatory myopathies.
Literatur
1.
Uruha A, Nishikawa A, Tsuburaya RS, Hamanaka K, Kuwana M, Watanabe Y, et al. Sarcoplasmic MxA expression: a valuable marker of dermatomyositis. Neurology. 2017;88(5):493–500.PubMedCrossRef
2.
Greenberg SA, Pinkus JL, Pinkus GS, Burleson T, Sanoudou D, Tawil R, et al. Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis. Ann Neurol. 2005;57(5):664–78.PubMedCrossRef
3.
Salajegheh M, Kong SW, Pinkus JL, Walsh RJ, Liao A, Nazareno R, et al. Interferon-stimulated gene 15 (ISG15) conjugates proteins in dermatomyositis muscle with perifascicular atrophy. Ann Neurol. 2010;67(1):53–63.PubMedPubMedCentralCrossRef
4.
Suárez-Calvet X, Gallardo E, Nogales-Gadea G, Querol L, Navas M, Díaz-Manera J, et al. Altered RIG-I/DDX58-mediated innate immunity in dermatomyositis. J Pathol. 2014;233(3):258–68.PubMedCrossRef
5.
De Luna N, Suárez-Calvet X, Lleixà C, Diaz-Manera J, Olivé M, Illa I, et al. Hypoxia triggers IFN-I production in muscle: implications in dermatomyositis. Sci Rep. 2017;7(1):8595.PubMedPubMedCentralCrossRef
6•.
Ladislau L, Suárez-Calvet X, Toquet S, Landon-Cardinal O, Amelin D, Depp M, et al. JAK inhibitor improves type I interferon induced damage: proof of concept in dermatomyositis. Brain. 2018;141(6):1609–21 This study validates a critical role of type I interferon pathway in the pathogenesis of dermatomyositis and suggests that it is a therapeutic target.PubMedCrossRef
7•.
Uruha A, Allenbach Y, Charuel JL, Musset L, Aussy A, Boyer O, et al. Diagnostic potential of sarcoplasmic myxovirus resistance protein A expression in subsets of dermatomyositis. Neuropathol Appl Neurobiol. 2019;45(5):513–22 This study, together with reference 1, demonstrates that immunostaining of myxovirus resistance A, one of the type I interferon-induced proteins, is useful for a diagnosis of dermatomyositis.PubMedCrossRef
8.
Allenbach Y, Leroux G, Suárez-Calvet X, Preusse C, Gallardo E, Hervier B, et al. Dermatomyositis with or without anti-melanoma differentiation-associated gene 5 antibodies: common interferon signature but distinct NOS2 expression. Am J Pathol. 2016;186(3):691–700.PubMedCrossRef
9.
Tanboon J, Uruha A, Stenzel W, Nishino I. Where are we moving in the classification of idiopathic inflammatory myopathies? Curr Opin Neurol. 2020;33(5):590–603.PubMedCrossRef
10.
Mammen AL, Allenbach Y, Stenzel W, Benveniste O. ENMC 239th Workshop Study Group. 239th ENMC International Workshop: Classification of dermatomyositis, Amsterdam, the Netherlands, 14-16 December 2018. Neuromuscul Disord. 2020;30(1):70–92.PubMedCrossRef
11.
Inoue M, Tanboon J, Okubo M, Theerawat K, Saito Y, Ogasawara M, et al. Absence of sarcoplasmic myxovirus resistance protein A (MxA) expression in antisynthetase syndrome in a cohort of 194 cases. Neuropathol Appl Neurobiol. 2019;45(5):523–4.PubMed
12.
Pinal-Fernandez I, Casal-Dominguez M, Derfoul A, Pak K, Plotz P, Miller FW, et al. Identification of distinctive interferon gene signatures in different types of myositis. Neurology. 2019;93(12):e1193–204.PubMedPubMedCentralCrossRef
13.
Soponkanaporn S, Deakin CT, Schutz PW, Marshall LR, Yasin SA, Johnson CM, et al. Expression of myxovirus-resistance protein A: a possible marker of muscle disease activity and autoantibody specificities in juvenile dermatomyositis. Neuropathol Appl Neurobiol. 2019;45(4):410–20.PubMedCrossRef
14.
Uruha A, Suzuki S, Nishino I. Author update: Sarcoplasmic MxA expression: a valuable marker of dermatomyositis. Neurology. 2017;89(2):215.PubMedCrossRef
15.
Manzano GS, Woods JK, Amato AA. Covid-19-associated myopathy caused by type I interferonopathy. N Engl J Med. 2020;383(24):2389–90.PubMedCrossRef
16••.
Bergua C, Chiavelli H, Allenbach Y, Arouche-Delaperche L, Arnoult C, Bourdenet G, et al. In vivo pathogenicity of IgG from patients with anti-SRP or anti-HMGCR autoantibodies in immune-mediated necrotising myopathy. Ann Rheum Dis. 2019;78(1):131–9 This study provides evidence of complement-mediated autoimmunity in the pathogenesis of immune-mediated necrotizing myopathy.PubMedCrossRef
17.
Allenbach Y, Benveniste O, Stenzel W, Boyer O. Immune-mediated necrotizing myopathy: clinical features and pathogenesis. Nat Rev Rheumatol. 2020;16(12):689–701.PubMedCrossRef
18.
Stenzel W, Preuße C, Allenbach Y, Pehl D, Junckerstorff R, Heppner FL, et al. Nuclear actin aggregation is a hallmark of anti-synthetase syndrome-induced dysimmune myopathy. Neurology. 2015;84(13):1346–54.PubMedCrossRef
19.
Mescam-Mancini L, Allenbach Y, Hervier B, Devilliers H, Mariampillay K, Dubourg O, et al. Anti-Jo-1 antibody-positive patients show a characteristic necrotizing perifascicular myositis. Brain. 2015;138(Pt 9):2485–92.PubMedCrossRef
20.
Uruha A, Suzuki S, Suzuki N, Nishino I. Perifascicular necrosis in anti-synthetase syndrome beyond anti-Jo-1. Brain. 2016;139(Pt 9):e50.PubMedCrossRef
21.
Uruha A, Suzuki S, Nishino I. Diagnosis of dermatomyositis: autoantibody profile and muscle pathology. Clin Exp Neuroimmunol. 2017;8:302–12.CrossRef
22.
Allenbach Y, Drouot L, Rigolet A, Charuel JL, Jouen F, Romero NB, et al. Anti-HMGCR autoantibodies in European patients with autoimmune necrotizing myopathies: inconstant exposure to statin. Medicine (Baltimore). 2014;93(3):150–7.CrossRef
23.
Watanabe Y, Uruha A, Suzuki S, Nakahara J, Hamanaka K, Takayama K, et al. Clinical features and prognosis in anti-SRP and anti-HMGCR necrotising myopathy. J Neurol Neurosurg Psychiatry. 2016;87(10):1038–44.PubMedCrossRef
24.
Nagaraju K, Raben N, Merritt G, Loeffler L, Kirk K, Plotz P. A variety of cytokines and immunologically relevant surface molecules are expressed by normal human skeletal muscle cells under proinflammatory stimuli. Clin Exp Immunol. 1998;113(3):407–14.PubMedPubMedCentralCrossRef
25.
Rodríguez Cruz PM, Luo YB, Miller J, Junckerstorff RC, Mastaglia FL, Fabian V. An analysis of the sensitivity and specificity of MHC-I and MHC-II immunohistochemical staining in muscle biopsies for the diagnosis of inflammatory myopathies. Neuromuscul Disord. 2014;24(12):1025–35.PubMedCrossRef
26.
Goebels N, Michaelis D, Wekerle H, Hohlfeld R. Human myoblasts as antigen-presenting cells. J Immunol. 1992;149(2):661–7.PubMedCrossRef
27.
Curnow SJ, Willcox N, Vincent A. Induction of primary immune responses by allogeneic human myoblasts: dissection of the cell types required for proliferation, IFNgamma secretion and cytotoxicity. J Neuroimmunol. 1998;86(1):53–62.PubMedCrossRef
28.
29.
Arahata K, Engel AG. Monoclonal antibody analysis of mononuclear cells in myopathies. I: quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells. Ann Neurol. 1984;16(2):193–208.PubMedCrossRef
30.
Ikenaga C, Kubota A, Kadoya M, Taira K, Uchio N, Hida A, et al. Clinicopathologic features of myositis patients with CD8-MHC-1 complex pathology. Neurology. 2017;89(10):1060–8.PubMedCrossRef
31.
Lloyd TE, Mammen AL, Amato AA, Weiss MD, Needham M, Greenberg SA. Evaluation and construction of diagnostic criteria for inclusion body myositis. Neurology. 2014;83(5):426–33.PubMedPubMedCentralCrossRef
32.
Uruha A, Noguchi S, Hayashi YK, Tsuburaya RS, Yonekawa T, Nonaka I, et al. Hepatitis C virus infection in inclusion body myositis: a case-control study. Neurology. 2016;86(3):211–7.PubMedCrossRef
33••.
Greenberg SA, Pinkus JL, Kong SW, Baecher-Allan C, Amato AA, Dorfman DM. Highly differentiated cytotoxic T cells in inclusion body myositis. Brain. 2019;142(9):2590–604 This study reveals that myofiber invasion by highly differentiated cytotoxic T cells, a marker of which is KLRG1, is specific to inclusion body myositis.PubMedCrossRef
34.
Knauss S, Preusse C, Allenbach Y, Leonard-Louis S, Touat M, Fischer N, et al. PD1 pathway in immune-mediated myopathies: pathogenesis of dysfunctional T cells revisited. Neurol Neuroimmunol Neuroinflamm. 2019;6(3):e558.PubMedPubMedCentralCrossRef
35.
De Bleecker JL, De Paepe B, Aronica E, de Visser M, ENMC Myositis Muscle Biopsy Study Group. 205th ENMC International Workshop: pathology diagnosis of idiopathic inflammatory myopathies part II 28-30 March 2014, Naarden, The Netherlands. Neuromuscul Disord. 2015;25(3):268–72.PubMedCrossRef
36.
Greenberg SA. Pathogenesis of inclusion body myositis. Curr Opin Rheumatol. 2020;32(6):542–7.PubMedCrossRef
37.
Nogalska A, Terracciano C, D’Agostino C, King Engel W, Askanas V. p62/SQSTM1 is overexpressed and prominently accumulated in inclusions of sporadic inclusion-body myositis muscle fibers, and can help differentiating it from polymyositis and dermatomyositis. Acta Neuropathol. 2009;118(3):407–13.PubMedCrossRef
38.
Girolamo F, Lia A, Annese T, Giannini M, Amati A, D’Abbicco D, et al. Autophagy markers LC3 and p62 accumulate in immune-mediated necrotizing myopathy. Muscle Nerve. 2019;60(3):315–27.PubMedCrossRef
39•.
Fischer N, Preuße C, Radke J, Pehl D, Allenbach Y, Schneider U, et al. Sequestosome-1 (p62) expression reveals chaperone-assisted selective autophagy in immune-mediated necrotizing myopathies. Brain Pathol. 2020;30(2):261–71 This report describes characteristic p62-positive aggregates in myofibers, suggesting involvement of chaperone-assisted selective autophagy in immune-mediated necrotizing myopathy.PubMedCrossRef
40.
De Visser M, Emslie-Smith AM, Engel AG. Early ultrastructural alterations in adult dermatomyositis. Capillary abnormalities precede other structural changes in muscle. J Neurol Sci. 1989;94(1-3):181–92.PubMedCrossRef
41.
Emslie-Smith AM, Engel AG. Necrotizing myopathy with pipestem capillaries, microvascular deposition of the complement membrane attack complex (MAC), and minimal cellular infiltration. Neurology. 1991 Jun;41(6):936–9.PubMedCrossRef
42.
Schröder NW, Goebel HH, Brandis A, Ladhoff AM, Heppner FL, Stenzel W. Pipestem capillaries in necrotizing myopathy revisited. Neuromuscul Disord. 2013 Jan;23(1):66–74.PubMedCrossRef
43.
Askanas V, Engel WK, Nogalska A. Sporadic inclusion-body myositis: a degenerative muscle disease associated with aging, impaired muscle protein homeostasis and abnormal mitophagy. Biochim Biophys Acta. 2015;1852(4):633–43.PubMedCrossRef
44.
Benveniste O, Stenzel W, Hilton-Jones D, Sandri M, Boyer O, van Engelen BG. Amyloid deposits and inflammatory infiltrates in sporadic inclusion body myositis: the inflammatory egg comes before the degenerative chicken. Acta Neuropathol. 2015;129(5):611–24.PubMedPubMedCentralCrossRef
45.
Askanas V, Engel WK, Alvarez RB, Glenner GG. beta-Amyloid protein immunoreactivity in muscle of patients with inclusion-body myositis. Lancet. 1992;339(8792):560–1.PubMedCrossRef
46.
Sarkozi E, Askanas V, Johnson SA, Engel WK, Alvarez RB. beta-Amyloid precursor protein mRNA is increased in inclusion-body myositis muscle. Neuroreport. 1993;4(6):815–8.PubMedCrossRef
47.
Askanas V, Alvarez RB, Engel WK. beta-Amyloid precursor epitopes in muscle fibers of inclusion body myositis. Ann Neurol. 1993;34(4):551–60.PubMedCrossRef
48.
Mirabella M, Alvarez RB, Bilak M, Engel WK, Askanas V. Difference in expression of phosphorylated tau epitopes between sporadic inclusion-body myositis and hereditary inclusion-body myopathies. J Neuropathol Exp Neurol. 1996;55(7):774–86.PubMedCrossRef
49.
Wilczynski GM, Engel WK, Askanas V. Association of active extracellular signal-regulated protein kinase with paired helical filaments of inclusion-body myositis muscle suggests its role in inclusion-body myositis tau phosphorylation. Am J Pathol. 2000;156(6):1835–40.PubMedPubMedCentralCrossRef
50.
Askanas V, Engel WK, Alvarez RB, McFerrin J, Broccolini A. Novel immunolocalization of alpha-synuclein in human muscle of inclusion-body myositis, regenerating and necrotic muscle fibers, and at neuromuscular junctions. J Neuropathol Exp Neurol. 2000;59(7):592–8.PubMedCrossRef
51.
Wilczynski GM, Engel WK, Askanas V. Cyclin-dependent kinase 5 colocalizes with phosphorylated tau in human inclusion-body myositis paired-helical filaments and may play a role in tau phosphorylation. Neurosci Lett. 2000;293(1):33–6.PubMedCrossRef
52.
Vattemi G, Engel WK, McFerrin J, Buxbaum JD, Pastorino L, Askanas V. Presence of BACE1 and BACE2 in muscle fibres of patients with sporadic inclusion-body myositis. Lancet. 2001;358(9297):1962–4.PubMedCrossRef
53.
Wojcik S, Engel WK, Yan R, McFerrin J, Askanas V. NOGO is increased and binds to BACE1 in sporadic inclusion-body myositis and in A beta PP-overexpressing cultured human muscle fibers. Acta Neuropathol. 2007;114(5):517–26.PubMedCrossRef
54.
Kannanayakal TJ, Mendell JR, Kuret J. Casein kinase 1 alpha associates with the tau-bearing lesions of inclusion body myositis. Neurosci Lett. 2008;431(2):141–5.PubMedCrossRef
55.
Weihl CC, Temiz P, Miller SE, Watts G, Smith C, Forman M, et al. TDP-43 accumulation in inclusion body myopathy muscle suggests a common pathogenic mechanism with frontotemporal dementia. J Neurol Neurosurg Psychiatry. 2008;79(10):1186–9.PubMedCrossRef
56.
Terracciano C, Nogalska A, Engel WK, Askanas V. In AbetaPP-overexpressing cultured human muscle fibers proteasome inhibition enhances phosphorylation of AbetaPP751 and GSK3beta activation: effects mitigated by lithium and apparently relevant to sporadic inclusion-body myositis. J Neurochem. 2010;112(2):389–96.PubMedCrossRef
57.
Nogalska A, Engel WK, Askanas V. Increased BACE1 mRNA and noncoding BACE1-antisense transcript in sporadic inclusion-body myositis muscle fibers--possibly caused by endoplasmic reticulum stress. Neurosci Lett. 2010;474(3):140–3.PubMedPubMedCentralCrossRef
58.
Nogalska A, D’Agostino C, Engel WK, Klein WL, Askanas V. Novel demonstration of amyloid-β oligomers in sporadic inclusion-body myositis muscle fibers. Acta Neuropathol. 2010;120(5):661–6.PubMedCrossRef
59.
D’Agostino C, Nogalska A, Cacciottolo M, Engel WK, Askanas V. Abnormalities of NBR1, a novel autophagy-associated protein, in muscle fibers of sporadic inclusion-body myositis. Acta Neuropathol. 2011;122(5):627–36.PubMedCrossRef
60.
Klingstedt T, Blechschmidt C, Nogalska A, Prokop S, Häggqvist B, Danielsson O, et al. Luminescent conjugated oligothiophenes for sensitive fluorescent assignment of protein inclusion bodies. Chembiochem. 2013;14(5):607–16.PubMedPubMedCentralCrossRef
61.
Yamashita S, Kimura E, Tawara N, Sakaguchi H, Nakama T, Maeda Y, et al. Optineurin is potentially associated with TDP-43 and involved in the pathogenesis of inclusion body myositis. Neuropathol Appl Neurobiol. 2013;39(4):406–16.PubMedCrossRef
62.
Cacciottolo M, Nogalska A, D’Agostino C, Engel WK, Askanas V. Dysferlin is a newly identified binding partner of AβPP and it co-aggregates with amyloid-β42 within sporadic inclusion-body myositis (s-IBM) muscle fibers. Acta Neuropathol. 2013;126(5):781–3.PubMedCrossRef
63.
Cacciottolo M, Nogalska A, D’Agostino C, Engel WK, Askanas V. Chaperone-mediated autophagy components are upregulated in sporadic inclusion-body myositis muscle fibres. Neuropathol Appl Neurobiol. 2013;39(7):750–61.PubMedCrossRef
64.
Ciryam P, Antalek M, Cid F, Tartaglia GG, Dobson CM, Guettsches AK, et al. A metastable subproteome underlies inclusion formation in muscle proteinopathies. Acta Neuropathol Commun. 2019;7(1):197.PubMedPubMedCentralCrossRef
65.
Banwell BL, Engel AG. AlphaB-crystallin immunolocalization yields new insights into inclusion body myositis. Neurology. 2000;54(5):1033–41.PubMedCrossRef
66.
Suzuki S, Uruha A, Suzuki N, Nishino I. Integrated diagnosis project for inflammatory myopathies: an association between autoantibodies and muscle pathology. Autoimmun Rev. 2017;16(7):693–700.PubMedCrossRef
67.
To F, Ventín-Rodríguez C, Elkhalifa S, Lilleker JB, Chinoy H. Line blot immunoassays in idiopathic inflammatory myopathies: retrospective review of diagnostic accuracy and factors predicting true positive results. BMC Rheumatol. 2020;4:28.PubMedPubMedCentralCrossRef
68.
Tansley SL, Li D, Betteridge ZE, McHugh NJ. The reliability of immunoassays to detect autoantibodies in patients with myositis is dependent on autoantibody specificity. Rheumatology (Oxford). 2020;59(8):2109–14.CrossRef
Metadaten
Titel
Updates on the Immunopathology in Idiopathic Inflammatory Myopathies
verfasst von
Akinori Uruha
Hans-Hilmar Goebel
Werner Stenzel
Publikationsdatum
01.07.2021
Verlag
Springer US
Erschienen in
Current Rheumatology Reports / Ausgabe 7/2021
Print ISSN: 1523-3774
Elektronische ISSN: 1534-6307
DOI
https://doi.org/10.1007/s11926-021-01017-7

Weitere Artikel der Ausgabe 7/2021

Current Rheumatology Reports 7/2021 Zur Ausgabe

Systemic Lupus Erythematosus (G Tsokos, Section Editor)

Updates on Clinical Trials in Systemic Lupus Erythematosus

Crystal Arthritis (M Pillinger and M Toprover, Section Editors)

Dietary and Lifestyle-Centered Approach in Gout Care and Prevention

Vasculitis (C Dejaco and C Duftner, Section Editors)

IgA Vasculitis in Adults: a Rare yet Challenging Disease

Systemic Lupus Erythematosus (G Tsokos, Section Editor)

Beyond Neuropsychiatric Manifestations of Systemic Lupus Erythematosus: Focus on Post-traumatic Stress Disorder and Alexithymia

Reactive Arthritis (H Zeidler, Section Editor)

Reactive Arthritis Update: Spotlight on New and Rare Infectious Agents Implicated as Pathogens

Correction

Correction to: Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION): 10-Year Update

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise